Literature DB >> 9448589

Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus.

G Sturfelt1, P Roux-Lombard, F A Wollheim, J M Dayer.   

Abstract

The objective was to study the relationship between the levels of interleukin-1 receptor antagonist (IL-1Ra) and disease activity and the acute-phase response in SLE patients with and without renal involvement. Twenty SLE patients who had distinct active clinical manifestations (eight glomerulonephritis, four systemic vasculitis without kidney involvement, nine skin rash, 12 arthritis, five serositis, four neuropsychiatric manifestations, three thrombocytopenia, one myositis and one haemolytic anaemia) were studied during a period of 8-12 months. Serum and plasma samples were taken at intervals of 6 weeks-4 months and tested for IL-1Ra, IL-1 beta, IL-6, IgG and anti-dsDNA, Clq, C3, C4 and C-reactive protein (CRP). IL-1Ra serum concentrations were increased in most SLE patients with active disease when compared to normal blood donors. However, at the time of flare, significantly higher levels of IL-1Ra were observed in patients with extra-renal disease as compared to other patients (median [range]: 363 [202-3041] and 4847 [268-27180] pg/ml for patients with and without renal involvement, respectively). This difference was not due to proteinuria. IL-1Ra levels did not correlate with SLEDAI score during flares, but they were elevated during flares in patients with extra-renal manifestations. When disease activity was at its highest, IL-1Ra concentrations correlated with IL-1 beta (r = 0.76; P < 0.001), IL-6 (r = 0.60; P < 0.01) and CRP (r = 0.61; P < 0.01), but not with C1q, C3, C4 and anti-dsDNA levels. The study showed that the pattern of inflammatory cytokines in active SLE varies in a manner that is dependent on which organs are involved. A relative absence of IL-1Ra response appears to be a feature characteristic of kidney involvement. IL-1Ra elevation clearly correlates with flares involving other organs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9448589     DOI: 10.1093/rheumatology/36.12.1283

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 3.  Cytokines as therapeutic targets in SLE.

Authors:  Lars Rönnblom; Keith B Elkon
Journal:  Nat Rev Rheumatol       Date:  2010-05-04       Impact factor: 20.543

Review 4.  New therapies for systemic lupus erythematosus.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 5.  The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus.

Authors:  Laurie S Davis; Jack Hutcheson; Chandra Mohan
Journal:  J Interferon Cytokine Res       Date:  2011-07-25       Impact factor: 2.607

6.  Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?

Authors:  E R Capper; J K Maskill; C Gordon; A I F Blakemore
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 7.  Anticytokine therapies in systemic lupus erythematosus.

Authors:  Antonio La Cava
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

8.  Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus.

Authors:  Zahra Tahmasebi; Mahmoud Akbarian; Sedigheh Mirkazemi; Abtin Shahlaee; Zahra Alizadeh; Ali Akbar Amirzargar; Ahmad Reza Jamshidi; Shima Ghoroghi; Shiva Poursani; Keramat Nourijelyani; Mahdi Mahmoudi
Journal:  Rheumatol Int       Date:  2013-05-31       Impact factor: 2.631

Review 9.  Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Pragnesh Mistry; Mariana J Kaplan
Journal:  Clin Immunol       Date:  2016-08-09       Impact factor: 3.969

10.  Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile.

Authors:  Sana Al-Mutairi; Adel Al-Awadhi; Raj Raghupathy; Hanaa Al-Khawari; Prio Sada; Adeebah Al-Herz; Parvez Rawoot
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.